1. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. (12th September 2018) Authors: Gadgeel, S; Peters, S; Mok, T; Shaw, A T; Kim, D W; Ou, S I; Pérol, M; Wrona, A; Novello, S; Rosell, R; Zeaiter, A; Liu, T; Nüesch, E; Balas, B; Camidge, D R Journal: Annals of oncology Issue: Volume 29:Number 11(2018) Page Start: 2214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. (24th May 2019) Authors: Mazieres, J; Drilon, A; Lusque, A; Mhanna, L; Cortot, A B; Mezquita, L; Thai, A A; Mascaux, C; Couraud, S; Veillon, R; Van den Heuvel, M; Neal, J; Peled, N; Früh, M; Ng, T L; Gounant, V; Popat, S; Diebold, J; Sabari, J; Zhu, V W Journal: Annals of oncology Issue: Volume 30:Number 8(2019) Page Start: 1321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗